{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:52:36Z","timestamp":1791924756155,"version":"4.3.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003645","name":"National Cancer Center, Korea","doi-asserted-by":"crossref","award":["2211610"],"award-info":[{"award-number":["2211610"]}],"id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Neuromuscular immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) have been increasingly recognized as a consequence of expanding use of ICIs in advanced cancers. We aimed to evaluate the frequency, phenotypes, rescue treatment, and clinical outcomes of severe neuromuscular irAEs of ICIs at National Cancer Center (NCC), Korea.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Consecutive patients with newly developed severe neuromuscular irAEs (common terminology criteria for adverse events grade 3 or greater) after ICI treatment at NCC in Korea between December 2018 and April 2022 were included by searching neuromuscular diagnostic codes in electronic medical records and\/or reviewing neurological consultation documentations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 1,503 ICI-treated patients, nine (0.6%) experienced severe neuromuscular irAEs; five with pembrolizumab and four with atezolizumab. The patients included five women and four men; their median age at onset was 59\u00a0years. The irAEs included Guillain\u2013Barre syndrome (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095) and myasthenia gravis (MG) crisis with myositis (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094), and developed after a median of one (range 1\u20135) ICI cycle. The median modified Rankin score (mRS) was 4 (range 3\u20135) at the nadir. ICIs were discontinued in all patients, and rescue immunotherapy included corticosteroids (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20099), intravenous immunoglobulin (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20097), and plasmapheresis (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092). Eight patients showed improvements, with a median mRS of 3 (range 1\u20134); however, one patient (who had MG crisis with myocarditis) died.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this real-world monocentric study, ICI-induced neuromuscular irAEs were rare but potentially devastating; thus, physicians should remain vigilant to enable prompt recognition and management of irAEs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-022-04516-x","type":"journal-article","created":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T11:02:31Z","timestamp":1670670151000},"page":"5583-5589","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea"],"prefix":"10.1007","volume":"149","author":[{"given":"Jae-Won","family":"Hyun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,10]]},"reference":[{"key":"4516_CR1","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1161\/01.STR.0000258355.23810.c6","volume":"38","author":"JL Banks","year":"2007","unstructured":"Banks JL, Marotta CA (2007) Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis. Stroke 38:1091\u20131096. https:\/\/doi.org\/10.1161\/01.STR.0000258355.23810.c6","journal-title":"Stroke"},{"key":"4516_CR2","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline. J Clin Oncol 36:1714\u20131768. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"4516_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39:1\u201310. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012","journal-title":"Immunity"},{"key":"4516_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","volume":"73","author":"S Cuzzubbo","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M et al (2017) Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 73:1\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.001","journal-title":"Eur J Cancer"},{"key":"4516_CR5","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/ana.25708","volume":"87","author":"D Dubey","year":"2020","unstructured":"Dubey D, David WS, Reynolds KL et al (2020) Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum. Ann Neurol 87:659\u2013669. https:\/\/doi.org\/10.1002\/ana.25708","journal-title":"Ann Neurol"},{"key":"4516_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/brain\/awt285","volume":"137","author":"C Fokke","year":"2014","unstructured":"Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC (2014) Diagnosis of Guillain-Barr\u00e9 syndrome and validation of brighton criteria. Brain 137:33\u201343. https:\/\/doi.org\/10.1093\/brain\/awt285","journal-title":"Brain"},{"issue":"4","key":"4516_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"JBAG Haanen","year":"2017","unstructured":"Haanen JBAG, Carbonnel F, Robert C et al (2017) Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(4):119\u2013142. https:\/\/doi.org\/10.1093\/annonc\/mdx225","journal-title":"Ann Oncol"},{"key":"4516_CR8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrd.2015.35","volume":"15","author":"A Hoos","year":"2016","unstructured":"Hoos A (2016) Development of immuno-oncology drugs-from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov 15:235\u2013247. https:\/\/doi.org\/10.1038\/nrd.2015.35","journal-title":"Nat Rev Drug Discov"},{"key":"4516_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001446.pub5","author":"RA Hughes","year":"2016","unstructured":"Hughes RA, Brassington R, Gunn AA, van Doorn PA (2016) Corticosteroids for guillain barre syndrome. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD001446.pub5","journal-title":"Cochrane Database Syst Rev"},{"key":"4516_CR10","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1016\/j.cllc.2019.10.008","volume":"21","author":"JW Hyun","year":"2020","unstructured":"Hyun JW, Kim GS, Kim SH et al (2020) Fatal simultaneous multi-organ failure following pembrolizumab treatment for refractory thymoma. Clin Lung Cancer 21:e74\u2013e77. https:\/\/doi.org\/10.1016\/j.cllc.2019.10.008","journal-title":"Clin Lung Cancer"},{"key":"4516_CR11","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","volume":"74","author":"JC Kao","year":"2017","unstructured":"Kao JC, Liao B, Markovic SN et al (2017) Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol 74:1216\u20131222. https:\/\/doi.org\/10.1001\/jamaneurol.2017.1912","journal-title":"JAMA Neurol"},{"key":"4516_CR12","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1007\/s00415-018-8890-z","volume":"265","author":"S Mancone","year":"2018","unstructured":"Mancone S, Lycan T, Ahmed T et al (2018) Severe neurologic complications of immune checkpoint inhibitors: a single-center review. J Neurol 265:1636\u20131642. https:\/\/doi.org\/10.1007\/s00415-018-8890-z","journal-title":"J Neurol"},{"key":"4516_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","volume":"106","author":"A Moreira","year":"2019","unstructured":"Moreira A, Loquai C, Pf\u00f6hler C et al (2019) Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer 106:12\u201323. https:\/\/doi.org\/10.1016\/j.ejca.2018.09.033","journal-title":"Eur J Cancer"},{"key":"4516_CR14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239\u2013245. https:\/\/doi.org\/10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"4516_CR15","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252\u2013264. https:\/\/doi.org\/10.1038\/nrc3239","journal-title":"Nat Rev Cancer"},{"key":"4516_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for immunotherapy of cancer (sitc) toxicity management working group. J Immunother Cancer 5:95. https:\/\/doi.org\/10.1186\/s40425-017-0300-z","journal-title":"J Immunother Cancer"},{"key":"4516_CR17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1634\/theoncologist.2018-0359","volume":"24","author":"KL Reynolds","year":"2019","unstructured":"Reynolds KL, Guidon AC (2019) Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: illustrative case and review of the literature. Oncologist 24:435\u2013443. https:\/\/doi.org\/10.1634\/theoncologist.2018-0359","journal-title":"Oncologist"},{"key":"4516_CR18","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMe1205943","volume":"366","author":"A Ribas","year":"2012","unstructured":"Ribas A (2012) Tumor immunotherapy directed at PD-1. N Engl J Med 366:2517\u20132519. https:\/\/doi.org\/10.1056\/NEJMe1205943","journal-title":"N Engl J Med"},{"key":"4516_CR19","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1212\/WNL.0000000000010632","volume":"95","author":"E Sechi","year":"2020","unstructured":"Sechi E, Markovic SN, McKeon A et al (2020) Neurologic autoimmunity and immune checkpoint inhibitors: autoantibody profiles and outcomes. Neurology 95:2442\u20132452. https:\/\/doi.org\/10.1212\/WNL.0000000000010632","journal-title":"Neurology"},{"key":"4516_CR20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","volume":"17","author":"JA Thompson","year":"2019","unstructured":"Thompson JA, Schneider BJ, Brahmer J et al (2019) Management of immunotherapy-related toxicities, version 1.2019. J Natl Compr Canc Netw 17:255\u2013289. https:\/\/doi.org\/10.6004\/jnccn.2019.0013","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04516-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04516-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04516-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T08:07:29Z","timestamp":1689754049000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04516-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,10]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["4516"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04516-x","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,10]]},"assertion":[{"value":"16 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ki Hoon Kim reports no financial disclosures. Jae-Won Hyun has received grants from the National Cancer Center and National Research Foundation of Korea. Su-Hyun Kim has lectured, consulted, and received honoraria from Bayer Schering Pharma, Biogen, Genzyme, Merck Serono, and UCB, and received a grant from the National Research Foundation of Korea. Ho Jin Kim has received a grant from the National Research Foundation of Korea, research support from Aprilbio and Eisai, consultancy\/speaker fees from Alexion, Aprilbio, Biogen, Celltrion, Daewoong, Eisai, GC Pharma, HanAll BioPharma, MDimune, Merck Serono, Novartis, Roche, Sanofi Genzyme, Teva-Handok, UCB, and Viela Bio, and is a co-editor for the Multiple Sclerosis Journal and an associated editor for the Journal of Clinical Neurology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board of NCC (No. NCC 2022\u20130142), and the requirement for patient informed consent was waived due to the use of anonymized data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval\/consent to participate\/consent to publish"}}]}}